Z
Zaza Katsarava
Researcher at I.M. Sechenov First Moscow State Medical University
Publications - 8
Citations - 292
Zaza Katsarava is an academic researcher from I.M. Sechenov First Moscow State Medical University. The author has contributed to research in topics: Health policy & Change management. The author has an hindex of 2, co-authored 8 publications receiving 31 citations.
Papers
More filters
Journal ArticleDOI
Migraine: epidemiology and systems of care
Messoud Ashina,Zaza Katsarava,Thien Phu Do,Dawn C. Buse,Patricia Pozo-Rosich,Aynur Özge,Abouch V. Krymchantowski,Elena R. Lebedeva,K. Ravishankar,Shengyuan Yu,Simona Sacco,Sait Ashina,Samaira Younis,Timothy J. Steiner,Richard B. Lipton +14 more
TL;DR: In this paper, the authors summarized the data on migraine epidemiology, including estimates of its very considerable burden on the global economy, and outlined the advantages of integrated and coordinated systems of care, in which primary and specialist care complement and support each other.
Journal Article
EHF-LTB Aids to management of headache disorders in primary care (2nd edition)
Timothy J. Steiner,RH Jensen,Zaza Katsarava,Mattias Linde,EA MacGregor,Paolo Martelletti,Osipova,Koen Paemeleire +7 more
TL;DR: The Aids to Management, with the European principles of management of headache disorders in primary care as the core of their content, combine educational materials with practical management aids.
Journal ArticleDOI
Headache service quality evaluation: implementation of quality indicators in primary care in Europe.
B. Lenz,Zaza Katsarava,Raquel Gil-Gouveia,G. Karelis,B. Kaynarkaya,L. Meksa,E. Oliveira,F. Palavra,I. Rosendo,M. Sahin,B. Silva,Derya Uluduz,Y. Z. Ural,I. Varsberga-Apsite,S. T. Zengin,L. Zvaune,Timothy J. Steiner,Timothy J. Steiner +17 more
TL;DR: In this article, the authors evaluated the effectiveness of a set of headache service quality indicators developed by lifting the burden (LTB) and European Headache Federation (EHF) in primary care.
Book ChapterDOI
The Healthcare Solution to Headache
Timothy J. Steiner,Rigmor Jensen,Zaza Katsarava,Derya Uluduz,Michela Tinelli,Hallie Thomas,Lars Jacob Stovner +6 more
TL;DR: This chapter builds on Chap.
Journal ArticleDOI
Social Impact of Prophylactic Migraine Treatments in Germany: A State-Transition and Open Cohort Approach.
TL;DR: Prescribed erenumab for the indicated population in Germany could lead to a reduction of 166 million migraine days annually and reduce productivity losses in the range of €27 billion, highlighting the macroeconomic effects of a systematic introduction of novel inhibitors of the calcitonin gene-related peptide pathway for migraine in Germany.